📇 Rhumatologue · CLERMONT FERRAND CEDEX 1 · (63) · Hospitalier
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
4 raisons identifiées
Auteur de référence en rhumatologie
38 articles scientifiques publiés — un praticien à la pointe de la recherche
Encadrant universitaire
Forme la prochaine génération de rhumatologues (1 thèse dirigée)
Expérience confirmée
32 ans d'exercice en rhumatologie — recul clinique solide
Délais de RDV courts dans la région
133.4 rhumatos / 100 000 hab. — département bien doté
32ans d'exercice (thèse 1994)
✨ Génération du profil synthétique IA en cours…
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
La carence martiale : donnees recentes ; etude prospective de la cinetique de reconstitution du statut en fer
Direction : Pierre Philippe
Source : catalogue national des thèses theses.fr (ABES). Ne couvre que les doctorats / HDR — les thèses d'exercice (DES) sont archivées dans les SCD universitaires.
Source theses.fr — signal de direction d'équipe / statut PU-PH (à confirmer via le site universitaire).
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Incidence, Characteristics, and Management of Venous Thrombosis in Adult Patients With Immune Thrombocytopenia: Results From the Multicenter, Prospective Registry CARMEN‐France
2026ArticleAmerican Journal of Hematology
Concordance between presenting features and relapse in granulomatosis with polyangiitis: implications for risk assessment and counselling
2025ArticleRMD Open
Diagnostic d’une hémolyse non auto-immune chez l’adulte
2025ArticleLa Revue de Médecine Interne
A clinical predictive score of high liver iron content in metabolic hyperferritinemia: a retrospective cohort pilot study
2025ArticleBMC Gastroenterology
Amoxicillin Blood Concentration in High-Dose Intravenous Discontinuous Amoxicillin: Look Beyond Numbers. Max-Amox Study
2024ArticleClinical Therapeutics
The CARMEN-France registry of adult patients with immune thrombocytopenia and autoimmune hemolytic anemia in France
2024ArticleLa Revue de Médecine Interne
Multisystemic Effects of Elexacaftor–Tezacaftor–Ivacaftor in Adults with Cystic Fibrosis and Advanced Lung Disease
2024ArticleAnnals of the American Thoracic Society
Substance use disorder of equimolar oxygen-nitrous oxide mixture in French sickle-cell patients: results of the PHEDRE study
2024ArticleOrphanet Journal of Rare Diseases
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
HOPITAL ESTAING - CHU63
1 PL LUCIE AUBRAC, 63003 CLERMONT FERRAND CEDEX 1
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Arthritis & rheumatology (Hoboken, N.J.) · 2017
ObjectiveIn most patients with nonsevere systemic necrotizing vasculitides (SNVs), remission is achieved with glucocorticoids alone, but one‐third experience a relapse within 2 years. This study was undertaken to determine whether the addition of azathioprine (AZA) to glucocorticoids could achieve a higher sustained remission rate of newly diagnosed nonsevere eosinophilic granulomatosis with polyangiitis (Churg‐Strauss) (EGPA), microscopic polyangiitis (MPA), or polyarteritis nodosa (PAN).MethodsAll patients included in this double‐blind trial received glucocorticoids, gradually tapered over 12 months, and were randomized to receive AZA or placebo for 12 months, with stratification according to SNV (EGPA or MPA/PAN). The primary end point was the combined rate of remission induction failures and minor or major relapses at month 24.ResultsNinety‐five patients (51 with EGPA, 25 with MPA, and 19 with PAN) met the inclusion criteria, were randomized, and received at least 1 dose of AZA (n = 46) or placebo (n = 49). At month 24, 47.8% of the patients receiving AZA versus 49% of the patients receiving placebo had remission induction failures or relapses (P = 0.86). Secondary end points were comparable between the AZA and placebo arms. These included initial remission rate (95.7% versus 87.8%), total relapse rate (44.2% versus 40.5%), and glucocorticoid use. Two patients in the placebo arm died; 22 patients in the AZA arm (47.8%) and 23 patients in the placebo arm (46.9%) experienced ≥1 severe adverse event. For EGPA patients, the primary end point (48% in the AZA arm versus 46.2% in the placebo arm) and the percent of patients who experienced asthma/rhinosinusitis exacerbations (24% in the AZA arm versus 19.2% in the placebo arm) were comparable between treatment arms.ConclusionAddition of AZA to glucocorticoids for the induction of remission of nonsevere SNVs does not improve remission rates, lower relapse risk, spare steroids, or diminish the EGPA asthma/rhinosinusitis exacerbation rate.
The American journal of medicine · 2017
Journal of autoimmunity · 2018
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Journal of internal medicine · 2026 · Journal Article
Pallotti F, Mettler C, Papo M, Iudici M, et al.
BMC gastroenterology · 2025 · Journal Article
Boughzala ML, Pereira B, Ruivard M, Lobbes H
Frontiers in medicine · 2024 · Journal Article
Sauvat L, Denis L, Nourrisson C, Poirier P, et al.
Clinical and experimental rheumatology · 2024 · Journal Article
Stuchfield-Denby E, Mattutzu V, Grobost V, André M, et al.
Annals of nutrition & metabolism · 2024 · Journal Article
Lobbes H, Dalle C, Pereira B, Ruivard M, et al.
The journal of allergy and clinical immunology. In practice · 2022 · Multicenter Study
Moyon Q, Pineton de Chambrun M, Gousseff M, Mathian A, et al.
Neurology · 2022 · Case Reports
Gavoille A, Desbois AC, Joubert B, Durel CA, et al.
American journal of hematology · 2022 · Journal Article
Mageau A, Terriou L, Ebbo M, Souchaud-Debouverie O, et al.
Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) · 2021 · Journal Article
Lahaye C, Gladine C, Pereira B, Berger J, et al.
Seminars in arthritis and rheumatism · 2020 · Journal Article
Roupie AL, Guedon A, Terrier B, Lahuna C, et al.
Rheumatology (Oxford, England) · 2019 · Journal Article
Puéchal X, Pagnoux C, Baron G, Lifermann F, et al.
Journal of clinical medicine · 2019 · Journal Article
Lobbes H, Dehos J, Pereira B, Le Guenno G, et al.
Internal medicine journal · 2019 · Journal Article
Le Guenno G, Guieze R, Audia S, Khellaf M, et al.
The American journal of medicine · 2017 · Journal Article
Pineton de Chambrun M, Gousseff M, Mauhin W, Lega JC, et al.
American journal of hematology · 2026 · Journal Article
Therme F, Viallard JF, Rueter M, Comont T, et al.
American journal of hematology · 2026 · Journal Article
Moulis G, Mahévas M, Viallard JF, Chèze S, et al.
Blood · 2023 · Observational Study
Guillet S, Loustau V, Boutin E, Zarour A, et al.
Blood advances · 2023 · Meta-Analysis
Lobbes H, Lega JC, Le Guenno G, Ruivard M, et al.
British journal of haematology · 2023 · Observational Study
Crickx E, Ebbo M, Rivière E, Souchaud-Debouverie O, et al.
JAMA network open · 2022 · Observational Study
Puéchal X, Iudici M, Perrodeau E, Bonnotte B, et al.
Seminars in arthritis and rheumatism · 2020 · Journal Article
Lobbes H, Dervout C, Toussirot E, Felten R, et al.
Journal of autoimmunity · 2018 · Journal Article
Mekinian A, Resche-Rigon M, Comarmond C, Soriano A, et al.
Blood advances · 2023 · Meta-Analysis
Lobbes H, Lega JC, Le Guenno G, Ruivard M, et al.
The European respiratory journal · 2022 · Journal Article
Stievenart J, Le Guenno G, Ruivard M, Rieu V, et al.
The Journal of rheumatology · 2022 · Systematic Review
Rheumatology (Oxford, England) · 2024 · Multicenter Study
Culerrier J, Nguyen Y, Karadag O, Yasar Bilge S, et al.
RMD open · 2022 · Comparative Study
Puéchal X, Iudici M, Pagnoux C, Cohen P, et al.
Frontiers in cardiovascular medicine · 2021 · Case Reports
Stievenart J, Le Guenno G, Ruivard M, Rieu V, et al.
European journal of haematology · 2018 · Journal Article
Lobbes H, Grobost V, Lemal R, Rieu V, et al.
Rheumatology (Oxford, England) · 2026 · Journal Article
Grobost V, Ramos M, Yelnik C, De Antonio M, et al.
Thrombosis research · 2023 · Letter
Fayard D, Lobbes H, Pereira B, Ruivard M
The European respiratory journal · 2022 · Journal Article
Stievenart J, Le Guenno G, Ruivard M, Rieu V, et al.
Clinical nutrition (Edinburgh, Scotland) · 2020 · Journal Article
Lobbes H, Gladine C, Mazur A, Pereira B, et al.
American journal of hematology · 2026 · Journal Article
Moulis G, Mahévas M, Viallard JF, Chèze S, et al.
Respiratory medicine · 2020 · Journal Article
Buvry C, Cassagnes L, Tekath M, Artigues M, et al.
Journal of autoimmunity · 2018 · Journal Article
Mekinian A, Resche-Rigon M, Comarmond C, Soriano A, et al.
American journal of hematology · 2026 · Journal Article
Moulis G, Mahévas M, Viallard JF, Chèze S, et al.
Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study
Abstract Background Paraneoplastic syndromes (PNS) are autoimmune disorders specifically associated with cancer. There are few data on anti-PD-1 or anti-PD-L1 immunotherapy in patients with a PNS. Our objective was to de
Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study
Abstract Background Paraneoplastic syndromes (PNS) are autoimmune disorders specifically associated with cancer. There are few data on anti-PD-1 or anti-PD-L1 immunotherapy in patients with a PNS. Our objective was to de
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
Nutrients · 2022 · Journal Article
Resseguier AS, Guiguet-Auclair C, Debost-Legrand A, Serre-Sapin AF, et al.
Rheumatology (Oxford, England) · 2022 · Journal Article
Iudici M, Pagnoux C, Courvoisier DS, Cohen P, et al.
Rheumatology (Oxford, England) · 2022 · Journal Article
Iudici M, Puéchal X, Pagnoux C, Courvoisier DS, et al.
Seminars in arthritis and rheumatism · 2021 · Journal Article
Iudici M, Pagnoux C, Courvoisier DS, Cohen P, et al.
Journal of autoimmunity · 2020 · Journal Article
Nguyen Y, Pagnoux C, Karras A, Quéméneur T, et al.
The European respiratory journal · 2022 · Journal Article
Stievenart J, Le Guenno G, Ruivard M, Rieu V, et al.
The Journal of rheumatology · 2022 · Systematic Review
Jeantin L, Lenfant T, Bataille P, de Boysson H, et al.
Jeantin L, Lenfant T, Bataille P, de Boysson H, et al.
Arthritis & rheumatology (Hoboken, N.J.) · 2017 · Journal Article
Puéchal X, Pagnoux C, Baron G, Quémeneur T, et al.